NCT05263583 - Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 9, 2022

Primary Completion Date

March 1, 2025

Study Completion Date

June 30, 2025

Conditions

High-grade B-cell LymphomaBurkitt LymphomaLymphoma, B-CellLymphoma, Large B-Cell, DiffuseLymphatic DiseasesLymphoma, High-GradeC-MYC/BCL2 Double-Hit High-Grade B-Cell LymphomaC-MYC/BCL6 Double-Hit High-Grade B-Cell LymphomaC-Myc Gene Rearrangement

Interventions

DRUG

Sepantronium Bromide

continuous intravenous infusion

Trial Locations (11)

Unknown

Beijing Cancer Hospital, Beijing

Sun Yat-sen University Cancer Center, Guangzhou

Henan Cancer Hospital, Henan

Shanghai East Hospital, Pudong

Tianjin Cancer Hospital, Tianjin

Tongji Hospital, Wuhan

Dong-A University Hospital, Busan

Inje University Haeundae Paik hospital, Busan

Samsung Medical Center, Seoul

Seoul National University Hospital, Seoul

Seoul St.Mary's Hospital, Seoul